A Prediction Model of Stable Warfarin Doses in Patients After Mechanical Heart Valve Replacement Based on a Machine Learning Algorithm
Open Access
- 26 June 2025
- journal article
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (6) , 33425
Abstract
Background: The narrow therapeutic range of warfarin, alongside the response of numerous influencing factors and significant inter-individual variability, presents major challenges for personalized medication. This study aimed to combine clinical and genetic characteristics with machine learning (ML) algorithms to develop and validate a model for predicting stable warfarin doses in patients from Northern China after mechanical heart valve replacement surgery. Methods: This study included patients who underwent mechanical heart valve replacement surgery at the Beijing Anzhen Hospital between January 2021 and January 2024 and achieved a stable warfarin maintenance dose. Comprehensive clinical and genetic data were collected, and patients were divided into training and validation cohorts at an 8:2 ratio through random division. The variables were selected using analysis of covariance (ANCOVA). Algorithms for predicting the stable warfarin dose were constructed using a traditional linear model, general linear model (GLM), and 10 ML algorithms. The performance of these algorithms was evaluated and compared using R-squared (R2), mean absolute error (MAE), and ideal prediction percentage to identify the optimal algorithm for predicting the stable warfarin dose and verify its clinical significance. Results: A total of 413 patients were included in this study for model training and validation, and 13 important features were selected for model development. The support vector machine radial basis function (SVM Radial) algorithm showed the best performance of all models, with the highest R2 value of 0.98 and the lowest MAE of 0.14 mg/day (95% confidence interval (CI): 0.11–0.17). This model successfully predicted the ideal warfarin dose in 93.83% of patients, with the highest ideal prediction percentage found in the medium-dose group (95.92%). In addition, the model demonstrated high predictive accuracy in both the low-dose and high-dose groups, with ideal prediction percentages of 85.71% and 92.00%, respectively. Conclusions: Compared to previous methods, SVM Radial demonstrates significantly higher accuracy for predicting the warfarin maintenance dose following heart valve replacement surgery, suggesting it has potential for widespread application. However, this study was based on a relatively small sample size and conducted at a single center. Future research should involve larger sample sizes and multicenter data to validate the predictive accuracy of the SVM Radial model further.Keywords
Funding Information
- Beijing Municipal Health Commission-The Capital Health Research and Development of Special (2020-2Z-2067)
This publication has 45 references indexed in Scilit:
- [The multicenter study on the registration and follow-up of low anticoagulation therapy for the heart valve operation in China].Zhonghua Yi Xue Za Zhi, 2016
- Influence of adult age on the total and free clearance and protein binding of (R)‐ and (S)‐warfarinBritish Journal of Clinical Pharmacology, 2012
- Genetic Warfarin DosingJACC, 2011
- VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest ChinaEuropean Journal of Clinical Pharmacology, 2010
- A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/RitonavirClinical Pharmacology & Therapeutics, 2010
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Effects of steatosis on drug-metabolizing capability of primary human hepatocytesToxicology in Vitro, 2007
- Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectivesThrombosis Research, 2007
- Cholesteryl Oligoarginine Delivering Vascular Endothelial Growth Factor siRNA Effectively Inhibits Tumor Growth in Colon AdenocarcinomaMolecular Therapy, 2006